New treatment to destroy abnormal cervical cells
Official title: Development of ablative therapy for the destruction of cervical neoplasia
Funded at Gynion, LLC · NIH-10919966 · Data updated 2026-11-12
This study is testing a new treatment for women with cervical intraepithelial neoplasia (CIN), a condition caused by HPV, to make sure it works well and is safe, so more women can get the care they need to prevent cervical cancer.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gynion, LLC NIH-funded |
| Lab location | 1 site (Trumbull, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $367,472 |
| NIH project number | 1R43CA285184-01A1 |
| Project ID | NIH-10919966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with cervical intraepithelial neoplasia (CIN) who are seeking treatment options.
✕Less likely to help
Patients who do not have cervical intraepithelial neoplasia or those who are not infected with oncogenic types of HPV may not benefit from this research.
What this research studies
This research focuses on developing a new ablative therapy aimed at treating cervical intraepithelial neoplasia (CIN), a precancerous condition caused by the Human Papilloma Virus (HPV). The approach seeks to overcome limitations of current treatments, such as cryotherapy and excisional procedures, which can be ineffective or carry risks for women. By creating a more effective and accessible treatment option, the research aims to ensure that more women diagnosed with CIN receive the necessary care to prevent progression to cervical cancer. The study will involve evaluating the safety and efficacy of this new therapy in a clinical setting.
Why it matters
Potential benefit: If successful, this research could provide a more effective and accessible treatment option for women with cervical intraepithelial neoplasia, potentially reducing the risk of cervical cancer.
How similar studies have gone: While current treatments for CIN have shown some success, this research aims to introduce a novel approach that has not been extensively tested in clinical settings.
Where this research is happening
-
Gynion, LLC
Trumbull, United States Active
Researchers
- Principal investigator: Shikhman, Oleg United States — Gynion, LLC
- Study coordinator: Shikhman, Oleg United States
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.